Clinical trial
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating…
NCT00467142 · Institut Bergonié, Other · Completed
Key facts
| NCT number | NCT00467142 |
|---|---|
| Title | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery |
| Official title | Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer |
| Acronym | OMEGA |
| Lead sponsor | Institut Bergonié, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug, Genetic |
| Interventions | bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, polymorphism analysis |
| Enrollment | 62 |
| Start date | Jan 23, 2007 |
| Primary completion | May 1, 2010 |
| Completion | Dec 1, 2011 |
| First posted | Apr 27, 2007 |
| Last update posted | Nov 1, 2022 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: